833 filings
Page 8 of 42
8-K
s57qx8n1n 4pft
10 Sep 20
Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine
7:32am
EFFECT
96oh1bg
31 Aug 20
Notice of effectiveness
12:15am
424B5
vn9mp9w
28 Aug 20
Prospectus supplement for primary offering
4:48pm
8-K
4q05 j1lwx
28 Aug 20
Entry into a Material Definitive Agreement
4:37pm
CORRESP
4620t867jnxi58vxf
26 Aug 20
Correspondence with SEC
12:00am
DEFA14A
wujxzspc pvjwst
13 Aug 20
Additional proxy soliciting materials
4:30pm
DEFA14A
sozqg2y 04nd334js
7 Aug 20
Additional proxy soliciting materials
4:37pm
CORRESP
eg9mcg80k3pm395zq
31 Jul 20
Correspondence with SEC
12:00am
UPLOAD
1c9j4 5a1mzopyuck
24 Jul 20
Letter from SEC
12:00am
8-K
qi39g
20 Jul 20
Soligenix Issues Corporate Update – Highlights Important Catalysts for Second Half of 2020
7:00am
8-K
6xgs4dg4sdqk55g c0sh
30 Apr 20
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
7:05am
8-K
iqpnqfwm4 of
13 Apr 20
Other Events
8:01am
8-K
b40uzd18o nilvxrt
10 Apr 20
Other Events
4:17pm